Last reviewed · How we verify
Subcutaneous infliximab CT-P13 Remsima®SC
Subcutaneous infliximab CT-P13 Remsima®SC is a Small molecule drug developed by Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. It is currently in Phase 2 development.
At a glance
| Generic name | Subcutaneous infliximab CT-P13 Remsima®SC |
|---|---|
| Sponsor | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Pharmacokinetic-pharmacodynamic Modeling and Simulation Study of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease
- A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Subcutaneous infliximab CT-P13 Remsima®SC CI brief — competitive landscape report
- Subcutaneous infliximab CT-P13 Remsima®SC updates RSS · CI watch RSS
- Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives portfolio CI
Frequently asked questions about Subcutaneous infliximab CT-P13 Remsima®SC
What is Subcutaneous infliximab CT-P13 Remsima®SC?
Subcutaneous infliximab CT-P13 Remsima®SC is a Small molecule drug developed by Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives.
Who makes Subcutaneous infliximab CT-P13 Remsima®SC?
Subcutaneous infliximab CT-P13 Remsima®SC is developed by Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives (see full Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives pipeline at /company/groupe-d-etude-therapeutique-des-affections-inflammatoires-digestives).
What development phase is Subcutaneous infliximab CT-P13 Remsima®SC in?
Subcutaneous infliximab CT-P13 Remsima®SC is in Phase 2.